Glutathione adducts induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1α and improve limb revascularization by Watanabe, Yosuke et al.
Glutathione adducts induced by ischemia and deletion
of glutaredoxin-1 stabilize HIF-1α and improve
limb revascularization
Yosuke Watanabea,b, Colin E. Murdocha,b,1, Soichi Sanob, Yasuo Idoc, Markus M. Bachschmida,b, Richard A. Cohena,b,
and Reiko Matsuia,b,2
aVascular Biology Section, Boston University School of Medicine, Boston, MA 20118; bWhitaker Cardiovascular Institute, Boston University School of
Medicine, Boston, MA 20118; and cSection of Endocrinology, Boston University School of Medicine, Boston, MA 20118
Edited by Gregg L. Semenza, Johns Hopkins University School of Medicine, Baltimore, MD, and approved April 15, 2016 (received for review December
14, 2015)
Reactive oxygen species (ROS) are increased in ischemic tissues and
necessary for revascularization; however, the mechanism remains
unclear. Exposure of cysteine residues to ROS in the presence of
glutathione (GSH) generates GSH-protein adducts that are specifi-
cally reversed by the cytosolic thioltransferase, glutaredoxin-1 (Glrx).
Here, we show that a key angiogenic transcriptional factor hypoxia-
inducible factor (HIF)-1α is stabilized by GSH adducts, and the genetic
deletion of Glrx improves ischemic revascularization. In mouse mus-
cle C2C12 cells, HIF-1α protein levels are increased by increasing GSH
adducts with cell-permeable oxidized GSH (GSSG-ethyl ester) or
2-acetylamino-3-[4-(2-acetylamino-2-carboxyethylsulfanyl thiocarbony-
lamino) phenylthiocarbamoylsulfanyl] propionic acid (2-AAPA), an
inhibitor of glutathione reductase. A biotin switch assay shows that
GSSG-ester-induced HIF-1α contains reversibly modified thiols, and
MS confirms GSH adducts on Cys520 (mouse Cys533). In addition, an
HIF-1α Cys520 serine mutant is resistant to 2-AAPA–induced HIF-1α
stabilization. Furthermore, Glrx overexpression prevents HIF-1α sta-
bilization, whereas Glrx ablation by siRNA increases HIF-1α protein
and expression of downstream angiogenic genes. Blood flow recov-
ery after femoral artery ligation is significantly improved in Glrx KO
mice, associated with increased levels of GSH-protein adducts, cap-
illary density, vascular endothelial growth factor (VEGF)-A, and HIF-
1α in the ischemic muscles. Therefore, Glrx ablation stabilizes HIF-1α
by increasing GSH adducts on Cys520 promoting in vivo HIF-1α stabiliza-
tion, VEGF-A production, and revascularization in the ischemic muscles.
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Despite the notion that increased oxidants are deleterious, clin-ical trials of antioxidant therapies failed to prevent cardiovas-
cular diseases (1). In mouse models, decreasing reactive oxygen
species (ROS) impaired ischemic revascularization after hind limb
ischemia (2, 3), and in contrast, increased ROS (4) or decreased
antioxidants (5) improved ischemic revascularization. Therefore,
ROS play a protective role in ischemic revascularization. However,
little is known about the molecular mechanism by which ROS im-
prove ischemic revascularization.
It is generally recognized that ROS change protein function by
posttranslational modifications of cysteine thiols (-SH) (6). Protein
thiols are susceptible to oxidation and give rise to reversible oxidative
modifications including S-sulfenylation (-SOH), S-nitrosylation
(-SNO), and glutathione (GSH)-protein adducts [S-glutathionylation
(-SSG)] (7). These reversible modifications can regulate cel-
lular signaling and may contribute to ROS-induced ischemic re-
vascularization. Interestingly, S-nitrosylation has been indicated as
a mechanism of nitric oxide (NO)-mediated signaling and shown to
stabilize hypoxia-inducible factor (HIF)-1α, a master angiogenic
transcriptional regulator (8).
S-nitrosylation and S-sulfenylation are chemically unstable and
further react with GSH, which is the most abundant small intracellular
thiol, to form GSH adducts (9, 10). A cytosolic thioltransferase,
glutaredoxin-1 (Glrx), specifically and efficiently catalyzes reduction of
GSH-protein adducts (11); thus, Glrx-regulated GSH-protein adducts
can affect redox signaling and play an important role in pathophysi-
ological conditions (12). The role of GSH-protein adducts of potential
in vivo target proteins in ischemic revascularization has not been
elucidated. We showed that Glrx overexpression impairs mouse is-
chemic revascularization (13). Here we hypothesized that GSH-pro-
tein adducts may prevent degradation of HIF-1α and that Glrx might
control HIF-1α activity by reversing GSH adducts. We demonstrate
that HIF-1α is stabilized by GSH adducts on Cys520 as a consequence
of ischemia or depletion of Glrx. Consistent with this, Glrx KO mice
have improved ischemic limb revascularization.
Results
Effect of GSH Adducts on HIF-1α Stabilization. To specifically increase
GSH-protein adducts in vitro, the cell membrane permeable oxidized
glutathione (GSSG)-ethyl ester (GSSG-EE) was used (9). C2C12 cells
treated for 10 h with GSSG-EE exhibited increased levels of HIF-1α
(Fig. 1A). Similarly, an inhibitor of glutathione reductase, 2-acetyla-
mino-3-[4-(2-acetylamino-2-carboxyethylsulfanyl thiocarbonylamino)
phenylthiocarbamoylsulfanyl] propionic acid (2-AAPA), which
increases GSH-protein adducts (14), increased HIF-1α protein
levels (Fig. S1). These data indicate that increased GSH-protein
adducts increase HIF-1α stabilization. A biotin switch assay was
performed to detect reversible oxidative thiol modification of
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HIF-1α. In this assay, modified cysteine thiols were reduced and
stably labeled with biotin-iodoacetamide (BIAM) followed by
pull-down using streptavidin beads as previously described (15).
GSSG-EE treatment increased overall levels of biotin-labeled
proteins in cell lysates of C2C12 cells (Fig. 1B) and confirmed that
GSSG-EE–treated cells contained higher levels of reversible mod-
ified proteins than vehicle-treated cells. HIF-1α was detected in the
pulled-down proteins, indicating that HIF-1α had reversible thiol
modifications augmented by GSSG-EE treatment (Fig. 1B).
To identify GSH-protein adducts of specific cysteine residues of
HIF-1α, MS was performed on recombinant human HIF-1α treated
with a mixture of GSSG/GSH. LC/MS/MS analysis showed that
among 15 cysteines in human HIF-1α, only 2 cysteine residues were
modified with GSH adduct and one of them was Cys520 (Fig. 1C).
This cysteine residue is conserved widely in vertebrate species and is
the only cysteine residue in the oxidant-dependent degradation
domain (ODD) of human HIF-1α (8). GSH-protein adducts do not
always affect protein function (12). To investigate the role of the
GSH adduct of Cys520, a Cys520→Ser mutant HIF-1α was gener-
ated. First, endogenous HIF-1α was knocked down by the CRISPR/
Cas9 system. Decreased protein levels of HIF-1α were confirmed
after induction by CoCl2 (Fig. S2A). Reconstitution of HIF-1α in
COS7 cells was performed by transfecting plasmids encodingWT or
C520S mutant HIF-1α to COS7 cells depleted of HIF-1α. Two days
after the transfection, 2-AAPA was used to induce GSH adduct-
dependent HIF-1α stabilization. Treatment with 2-AAPA increased
HIF-1α expression in WT HIF-1α, but not in Cys520 HIF-1α
mutant-transfected cells (Fig. 1 D and E). In normoxia, HIF-1α is
hydroxylated by oxygen-dependent prolyl hydroxylase, and hydrox-
ylated HIF-1α is ubiquitinated by attachment of the E3 ubiquitin
ligase, von Hippel–Lindau tumor suppressor protein (pVHL), to
the ODD leading to proteasomal degradation (16, 17). To elucidate
the mechanism of HIF-1α stabilization, we tested whether pVHL
attachment to HIF-1α is decreased by GSH adduct on Cys520 lo-
cated in the ODD. To examine this protein interaction, cell lysate of
HEK293T cells expressing Flag-tagged WT or C520S mutant HIF-
1α was treated with GSSG to increase GSH adducts on HIF-1α,
and then coimmunoprecipitation (Co-IP) was performed with
cell lysates containing HA-pVHL. As expected, pVHL attach-
ment was decreased by GSSG treatment in WT but not in C520S
mutant HIF-1α cell lysates (Fig. 1F). Expression and hydroxyl-
ation levels of HIF-1α were not different in WT or C520S mutant
HIF-1α–expressing cells (Fig. S3).
Regulation of HIF-1α and Angiogenic Genes by Glrx. The levels of
protein-GSH adducts are specifically regulated by gain and loss of
function of Glrx (13, 18). To analyze the effect of removal of GSH
adducts by Glrx on HIF-1α stabilization, Glrx was overexpressed in
COS-7 cells using adenoviral tetracycline-responsive element–
driven Glrx (Ad tet-Glrx) (19), and doxycycline was added to in-
duce Glrx in Ad tet-Glrx–transfected cells. Glrx overexpression
decreased accumulation of HIF-1α induced by 2-AAPA (Fig. 2 A
and B). Also, the effect of Glrx ablation was analyzed by adding
siRNA to mouse Glrx (siGlrx) in C2C12 cells. Glrx protein was
almost completely knocked down in C2C12 cells by siGlrx (Fig.
2C). HIF-1α was significantly increased in cells treated with siGlrx
compared with control siRNA (Fig. 2 C and D). The biotin switch
assay confirmed that siGlrx-treated cells contained higher levels of
proteins with reversibly oxidized thiols including HIF-1α, indicating
that HIF-1α had reversible thiol modifications augmented by Glrx
inhibition (Fig. S4). Although HIF-1α protein was increased, Glrx
ablation did not affect mRNA levels of HIF-1α (Fig. 2E), indicating
that HIF-1α was regulated at the protein level. Furthermore, in
siGlrx-treated cells, mRNA expression of HIF-1α−dependent an-
giogenic genes was increased compared with control including
Vegfa, Pdgf (platelet-derived growth factor) a, Pdgfb, and Fgf
(fibroblast growth factor) 2 (Fig. 2F), indicating that HIF-1α tran-
scriptional activity was increased by siGlrx. Furthermore, the effect
of Glrx knockdown on HIF-1α stabilization was eliminated by
overexpression of human Glrx, which is resistant to mouse siGlrx
(Fig. 2G). To confirm that the increase in angiogenic genes caused
by Glrx knockdown depends on HIF-1α, Glrx knockdown by
siRNA was performed to C2C12 cells in which the HIF-1α gene was
knocked down by CRISPR/Cas9. Levels of HIF-1α in HIF-1α
knockdown cells were 52% of that in control cells after CoCl2 treat-
ment (Fig. S2B). The increase in Vegfa mRNA expression caused by
siGlrx was eliminated in cells with the HIF-1α knockdown (Fig. 2H).
Lack of Glrx Improves Ischemic Hind Limb Revascularization in Mice.
GSH-protein adducts were increased in ischemic hind limbs; in
contrast, GSH protein adducts were decreased in transgenic mice
overexpressing Glrx, resulting in impaired revascularization (13).
Here, to determine the role of endogenous Glrx on ischemic re-
vascularization, hind limb ischemia was induced in Glrx KO and
WT littermate controls. A mouse model of peripheral artery dis-
ease was created in 10- to 12-wk-old male mice by excising a 5-mm
segment of left femoral artery. Blood flow was measured serially by
using LASER (light amplification by stimulated emission of radi-
ation) Döppler before, immediately after hind limb ischemic sur-
gery, and at days 3, 7, and 14 (Fig. 3A). Notably, blood flow
recovery after hind limb ischemia was significantly improved inGlrx
KO mice compared with WT littermates (Fig. 3B). After 14 d, the
blood flow in ischemic limbs returned to 91% of nonischemic limbs
in Glrx KO mice, whereas it was still 70% in WT mice. In addition,
histological analysis of ischemic limbs 7 d after surgery showed that
necrotic areas, characterized by loss of muscle fibers and infiltration
of inflammatory cells that appeared in WT mice, were less obvious
in the ischemic limb ofGlrx KOmice (Fig. 3C). Capillary density in
nonischemic limbs was not different between Glrx KO mice and
WT mice, but capillary density, which is increased in ischemic limbs
of WT mice, was increased to a greater extent in Glrx KO mice
(Fig. 3 D and E). To analyze GSH-protein adducts in ischemic
limbs, an immunoblot using anti-GSH antibody was performed on
muscle proteins under nonreducing conditions. The levels of GSH-
protein adducts were not different in nonischemic limbs between
Glrx KO and WT mice. Levels increased in ischemic limbs of both
types of mice, but the increase was significantly greater in Glrx KO
ischemic limbs (Fig. 3 F and G). Similarly, the levels of oxidatively
modified proteins detected by the biotin switch assay were greater
in Glrx KO ischemic limbs than WT ischemic limbs (Fig. S5). In-
creases in HIF-1α and VEGF-A in ischemic limbs were significantly
greater in Glrx KO mice than in WT mice (Fig. 3 H–J).
To explore the roles of Glrx in myeloid cells in blood flow re-
covery, bone marrow from Glrx KO mice and WT littermates was
transplanted to WT recipient mice. Expression of Glrx in bone
marrow was eliminated, but not in limb muscle, after Glrx KO
marrow transplantation (Fig. S6A). Interestingly, Glrx KO marrow
transplantation had no effect on blood flow recovery after hind
limb ischemia surgery (Fig. S6B), indicating that Glrx in resident
tissue cells was more important in regulating blood flow recovery.
Discussion
GSH-protein adducts (S-glutathionylation) has emerged as an im-
portant oxidative thiol modification that regulates signaling molecules
and transcription factors (6, 7, 9, 12). This modification is specifically
reversed by Glrx, a ubiquitous cytosolic enzyme. Although many
proteins are functionally regulated by GSH adducts (20–23), Glrx-
mediated functional control in vivo is not shown for many molecules
(24). The previously unidentified findings in this study are (i) that
HIF-1α stability is regulated by glutathione adducts and by endoge-
nous Glrx in vivo during ischemia, (ii) that glutathione adducts sta-
bilize HIF-1α by preventing pVHL binding despite hydroxylation, and
(iii) that endogenous Glrx significantly suppresses ischemic re-
vascularization, making it a therapeutic target. This study provides
one of the mechanisms that ROS stimulate ischemic revascularization
and emphasizes caution in the use of antioxidants for ischemia.
HIF-1α is a key regulator of the response to hypoxia and is me-
diated by the HIF-1α subunit and the constitutively expressed HIF-
1β subunit. Hypoxia inactivates prolyl hydroxylase and stabilizes
HIF-1α by preventing protein degradation. HIF-1α is a major factor
contributing to ischemic revascularization (25, 26). Interestingly,
previous reports indicated NO-induced HIF-1α stabilization by
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S-nitrosylation (27) and showed that Cys533 (equivalent to human
Cys520) in the ODD was critical for NO-induced dissociation of
the ODD from pVHL to prevent HIF-1α degradation (8). We
detected GSH adduct on Cys520 of human HIF-1α by MS, and by
using a HIF-1α Cys520 Ser mutant, confirmed that GSH adducts
on this cysteine are critical for preventing binding to pVHL and
HIF-1α stabilization.
To distinguish S-nitrosylation from GSH-protein adducts in vivo
is technically difficult because (i) reactive nitrogen species such as
S-nitrosoglutathione (GSNO) or peroxynitrite (ONOO−) can
induce both S-nitrosylation and GSH-protein adducts (9, 28), (ii)
S-nitrosylation is chemically unstable and can react with GSH to
become relatively more stable GSH adducts (9, 10), and (iii) biotin
switch assays are not very specific to distinguish these reversible
modifications (29). In our study, HIF-1α stabilization was induced
by GSSG-EE in C2C12 cells under conditions of minimal nitro-
sative stress, and its stabilization was regulated by Glrx, which
specifically reverses GSH-protein adducts. Furthermore, Glrx de-
letion in vivo stabilized HIF-1α and promoted revascularization, but
levels of S-nitrosylated proteins detected by an ascorbate-dependent
biotin switch assay were not different either between ischemic and
nonischemic limbs or between WT and Glrx KO limbs (Fig. S7).
These data contrast with increased GSH adducts in ischemic mus-
cles and further increases in the Glrx KO mouse shown by Western
blot (Fig. 3F) and by data on DTT-reducible thiol adducts obtained
with the biotin switch assay (Fig. S5). These results indicate a sig-
nificant role of GSH adducts, rather than S-nitrosylation per se, in
HIF-1α stabilization and ischemic angiogenesis.
The effects of ischemia in vivo are caused not only by hypoxia, but
ROS are also produced by mitochondria, NADPH oxidases, and
other sources (30). Previous studies indicated that ROS transduce
angiogenic signaling and promote revascularization (4). Our data
suggest that ROS promote ischemic revascularization at least in part
by increasing GSH adducts on HIF-1α. Therefore, increased levels of
GSH-protein adducts in ischemic muscle in WT mice may not
merely be an indication of oxidative stress but rather are evidence of
a pathophysiological response that facilitates revascularization.
Previously, we reported that Glrx-overexpressing transgenic (TG)
mice had impaired ischemic limb revascularization in association
with enhanced endothelial NF-κB activity and increased plasma
levels of the antiangiogenic soluble VEGFR1 (sFlt1) (13). NF-κB
may increase inflammation and sFlt1 induction, but endothelial
NF-κB KO impaired blood flow recovery in ischemic hind limb
(31). Therefore, although Glrx deletion may inactivate NF-κB by
GSH-protein adducts on IKK-β (22) or p50 (23), NF-κB in-
activation per se cannot explain improved blood flow in Glrx KO
mice. Also, plasma sFlt1 levels were not different betweenGlrx KO
and WT mice after hind limb ischemia (Fig. S8). Our interpretation
is that superphysiological overexpression of Glrx induces sFlt1, but
endogenous Glrx has little effect on sFlt1 expression. From our TG
and KO mice studies, we can conclude that Glrx has antiangiogenic
actions in vivo, but the mechanisms that explain the phenotypes are
complex and may also include regulation of additional proteins
by GSH adducts including sarcoendoplasmic reticulum calcium
ATPase (21, 32) and tyrosine phosphatase PTP1B (20). However,
the increase in VEGF-A expression induced by siGlrx was de-
pendent on HIF-1α in C2C12 cells (Fig. 2H), indicating that HIF-1α
is the major mediator of proangiogenic responses by Glrx ablation.
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Fig. 1. Effect of GSH adduct on HIF-1α stabilization. (A) Effect of GSSG-
ethyl-ester on HIF-1α stabilization in C2C12 cells. After differentiation, C2C12
cells were treated with 50 μg GSSG-ethyl ester or PBS for 10 h. Representa-
tive Western blot of HIF-1α and β-tubulin (Upper) and densitometry analysis
of HIF-1α normalized by β-tubulin (Lower) (n = 8 each group). (B) Biotin
switching assay for detection of HIF-1α reversible oxidative modification.
DTT-dependent oxidative modified cysteines were labeled with biotin. Then
biotin labeled protein was pull-downed using streptavidin beads. (B) Im-
munoblot of HIF-1α (Upper Left) and total reversible oxidative modified
proteins detected by dye conjugated streptavidin (Lower Left) in a total
sample. Immunoblot of HIF-1α (Upper Right) and total reversible oxidative
modified proteins (Lower Right) in pulled down proteins. (C) Identification
of Cys520 GSH adduct by MS. GSH adduct of Cys520 was detected from elas-
tase fragment 520CFYVDSDMV528. The actual mass of this fragment was
1,939.48 (m/z = 700.252+), which was 321 Da more than the original MW. The
MS/MS analysis showed that this fragment modified at Cys520 by GSH adduct
(+305 Da) and Met527 by oxidation (+16 Da). (D and E) C520S mutation
decreased 2-AAPA–dependent stabilization of HIF-1α. Plasmids that included
WT and C520S mutant HIF-1α were transfected to COS7 cells in which
endogenous HIF-1α was deleted by CRISPR/Cas9. These cells were treated
with 20 μmol/L 2-AAPA for 3 h. (D) Representative Western blot of HIF-1α
and β-tubulin. (E) Densitometry analysis, data were expressed as HIF-1α in-
duction ratio of 2-AAPA–treated cells to respective vehicle-treated cells (n =
4 each group). (F) Western blotting analysis following Co IP of HA-VHL
overexpressed cell lysate and GSSG-treated Flag-tagged WT or C520S mutant
HIF-1α–overexpressed cell lysate by anti-HA antibody. Detection of Flag-
tagged HIF-1α and HA-tagged VHL was performed by anti-Flag antibody and
anti-VHL antibody, respectively. Experiments were repeated three times
with similar results. *P < 0.05.
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Although we used global Glrx KO mice, a potential role of
endogenous Glrx in myeloid cells in ischemic vascularization was
excluded by bone marrow transplantation studies. Because Glrx is
expressed ubiquitously, however, it remains unclear which type(s) of
resident cells are important in theGlrx KO. Our Glrx KO mice data
are consistent with endogenous Glrx orchestrating antiangiogenic
actions through GSH adducts on HIF-1α and potentially other
proteins. Therefore, down-regulation of Glrx itself can be a potential
therapeutic target to promote ischemic limb revascularization.
In conclusion, GSH adducts on HIF-1α Cys520 induced by is-
chemia and Glrx deletion stabilize the protein and improves re-
vascularization after hind limb ischemia in mice. Glrx ablation may
be a therapeutic strategy to locally induce angiogenic genes in
ischemic limbs.
Materials and Methods
Reagents. Cell culture reagents were obtained from Invitrogen. Reduced glu-
tathione (G4251), oxidized glutathione (G4376), and 2-AAPA were from Sigma
Aldrich. Anti–β-tubulin antibody (2128) and anti–hydroxy-HIF-1α antibody
(3434) were from Cell Signaling, anti-GSH antibody was from Virogen (101-A-
100), anti–HIF-1α polyclonal antibody was from Cayman (10006421), anti-VEGF
antibody was from Santa Cruz Biotechnology (sc-152), anti-Flag antibody was
from Sigma Aldrich (F7425), and anti-VHL antibody was from BD Pharmingen
(556347). Human and mouse Glrx antibodies were custom ordered from Bethyl
Laboratories. Human HIF-1α plasmid was from Sino Biological (HG11977-NH).
Recombinant HIF-1α was from Abnova (H00003091-P01).
Cell Culture. C2C12 myoblast cells were grown in DMEM supplemented with
10% (vol/vol) FBS. For differentiation to myotubes, C2C12 cells were cultured in
DMEM with 1% FBS for 5 d before experiments. Validated stealth siRNA oli-
gonucleotides to Glrx were purchased from Invitrogen. Transfection of siRNA
against Glrx (CCUACUGCAGAAAGACCCAAGAAAU, AUUUCUUGGGUCUUUC-
UGCAGUAGG) or nonsilencing control (CCUACGUAAAGCCAGGAACACAAAU,
AUUUGUGUUCCUGGCUUUACGUAGG) to C2C12 cells was performed using
Viromer Blue (VB-01LB; Lipocalyx) twice following the manufacturer’s protocol
before differentiation. For human Glrx overexpression in C2C12 cells, ad human
Glrx (13) was transfected to undifferentiated C2C12 cells for 3 h. Then medium
was changed to DMEM containing 1% FBS for differentiation 3 d after trans-
fection cells were lysed and used for the following experiment. For GSSG ester
treatment, medium was changed to DMEM without FBS, and these cells were
treated with 50 μmol/L GSSG ester for 10 h. COS7 cells were seeded to 6-well
plates and transfected with WT HIF-1α and C520S mutant HIF-1α (0.25 μg/well)
using Lipofectamin 2000 (0.5 μL/well). These cells were treated with 20 μmol/L
2-AAPA for 3 h in serum-free DMEM 2 d after transfection. Adenoviral vector that
expresses adenoviral tetracycline-responsive element–driven Glrx-conjugated
GFP protein (Ad tet-Glrx) was a generous gift from Reto Asmis, University of
Texas Health Science Center, San Antonio. Glrx overexpression was induced by
using Ad tet-Glrx as described previously (19) by adding doxycycline (1 μg/mL)
overnight. No human samples are used in this study. Work with human cells
and plasmids was approved by the Boston University Medical Campus in-
stitutional biosafety committee.
HIF-1α Knockdown by CRISPR/Cas9. pSpCas9(BB)-2A-Puro (PX459) V2.0 plasmid
used for generating a CRISPR-Cas9 endonuclease was a gift from Feng Zhang,
Broad Institute, Massachusetts Institute of Technology, Cambridge, MA,
obtained via Addgene (Addgene plasmid 62988). HIF-1a KO by CRISPR/Cas9 was
performed as described previously with slight modifications (33). Insert oligo-
nucleotides that include a guiding RNA sequence were designed as follows: for
KO green monkey HIF-1α (COS7 cells), CACCGCGGGGACCGATTCACCATGG and
AAACCCATGGTGAATCGGTCCCCGC; and for KO mouse HIF-1α (C2C12 cells),
CACCGCACCCTAACAAGCCGGGGG, AACCCCCCGGCTTGTTAGGGTGC. After anneal-
ing, these oligonucleotides were inserted to the BbsI cloning site of PX459.
These plasmids and unmodified PX459 plasmid were transfected to COS7
cells and C2C12 cells by using Lipofectamin 2000, respectively. Puromycin
selection was performed after 1-d transfection for 2 d. After selection, cells
were expanded and used for experiments.
Synthesis of Oxidized Glutathione Ethyl Ester. Oxidized glutathione was es-
terified using acetyl chloride to produce an oxidized glutathione glycine-
O-monoethyl ester. Briefly, 1 mol/L acetyl chloride in ethanol was prepared
by adding 1.8 mL acetyl chloride (Sigma Aldrich) to 25 mL ice cold anhydrous
ethanol. After 15 min, 2.5 g oxidized glutathione was dissolved and incubated
on a rotator for 2 h at room temperature. The progress of the reaction was
followed by TLC. When at least 98% of the oxidized glutathione has dis-
appeared (about 2 h), the mixture was cooled on ice, and 25 mL cold ethanol
was added. The solution was adjusted to pH 6 with triethylamine to precipitate
the oxidized glutathione mono ethylester. The product was dried, triturated
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Fig. 2. Regulation of HIF-1α and angiogenic genes by Glrx. (A and B) Glrx
overexpression decreased 2-AAPA–dependent HIF-1α stabilization. Ad tet-Glrx
was transfected to COS7 cells. After Glrx overexpression was induced by 1 μg
doxycycline, these cells were treated with 2-AAPA. (A) Representative Western
blot of HIF-1α, β-tubulin, and Glrx. (B) Densitometry analysis of HIF-1α nor-
malized by β-tubulin (n = 4 each group). Glrx knockdown increased HIF-1α and
angiogenic genes expression. (C and D) Glrx knockdown by siGlrx increased HIF-1α
and angiogenic genes in C2C12 cells. (C) Representative Western blot of HIF-1α,
β-tubulin, and Glrx. (D) Densitometry analysis of HIF-1α (n = 8 each group).
(E) Relative mRNA expression of HIF-1α, (F) mRNA of Vegfa, Pdgfa, Pdgfb, and
Fgf2 (n = 6 each group) in siGlrx-treated C2C12 cells. (G) Overexpression of
human Glrx effect on HIF-1α stabilization by Glrx knockdown. Glrx knock-
downed C2C12 cells by siGlrx were transfected with ad human Glrx, which is
resistant to siGlrx. Levels of HIF-1α, human, and mouse Glrx were analyzed by
Western blotting. (H) Effect of HIF-1α knockdown on increment of mRNA levels
of Vegfa by siGlrx. HIF-1α was knocked down by CRISPR/Cas9 in C2C12 cells.
Then effect of siGlrx on mRNA expression of Vegfa was analyzed by qPCR. †P <
0.05, compared with respective vehicle-treated cells, *P < 0.05.
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with dry t-butyl ether and ethanol, washed several times with t-butyl ether, and
dried. The final product was dissolved in double distilled water and purified by
Diaion HP20SS (Sigma Aldrich) column chromatography through stepwise elu-
tion with an increasing concentration of ethanol in water. The fraction con-
taining oxidized glutathione glycine-O-monoethyl ester was lyophilized.
Mutagenesis Procedures. Plasmid that includedhuman full-length cDNAofHIF-1α
was used to construct Cys520 mutant HIF-1α. The Cys520→Ser mutation was per-
formed using the QuikChange II site-directed mutagenesis kit (200523; Agilent
Technologies). Primers were designed as follows: GCCTAATAGTCCCAGTGAA-
TATTCTTTTTATGTGGATAGTGATATGG and CCATATCACTATCCACATAAAAAGA-
ATATTCACTGGGACTATTAGGC. The sequence of the construct was verified for
DNA sequences (Tuft Medical Center, Sequencing Core). The Flag tag was added
to the 5′ end by PCR to WT and C520S mutant HIF-1α. Primers were designed
as follows, which include BamHI recognition and the Flag sequence for the 5′
end and the NotI recognition sequence for the 3′ end: forward, CGGGATC-
CATGGATTACAAGGATGACGACGATAAGGGTGGAGGCGGTAGCGAGGG; reverse,
ATAGTTTAGCGGCCGCTTAGTTAACTTGATCCAAAGCTC. Then, the PCR product
was inserted into pcDNA3.1, which cleaved with BamHI and NotI.
Co-IP Assay. HEK 293T cells in a 10-cm dish were transfected with 5 μg FlagWT
HIF-1α, C520S mutant HIF-1α, or HA-VHL-pRc/CMV (34), which was a gift from
William Kaelin, Dana-Farber Cancer Institute, Harvard Medical School, Boston,
MA, via addgene (Addgene plasmid 19999) by using Lipofectamin 2000. WT or
C520S mutant HIF-1α–transfected cells were lysed with 25 mmol/L Tris·HCl, 150
mmol/L NaCl, 10 mmol/L EDTA, 1% Triton, 1× protease, phosphatase inhibitor
mixture (PI78441; Theromo Scientific), and lysate, which contains 500 μg pro-
tein treated with 100 mmol/L GSSG for 10 h. Then, desalting was performed
with a Zeba column (89889; Thermo Fisher Scientific) to remove GSSG. These
samples were mixed with 250 μg HA-VHL–transfected cell lysate, and Co IP was
performed using a Pierce HA-Tag Magnetic IP/Co-IP kit (88838; Thermo Fisher
Scientific). Detection of Flag–HIF-1α or HA-VHL was performed by immuno-
blotting by using anti-Flag antibody or anti-VHL antibody, respectively.
MS. HIF-1α recombinant protein (4 μg) was incubated with 25 mmol/L Tris·HCl,
30 mmol/L GSSG, and 70 mmol/L GSH, pH 8.0, for 12 h at room temperature and
separated by SDS/PAGE. After electrophoresis, the gel was stained with Impe-
rial protein stain (Thermo Fischer Scientific), and the band of HIF-1α was ex-
cised. The gel was washed with 25 mmol/L ammonium bicarbonate followed by
acetonitrile three times. Digestion was performed with elastase at 37 °C for 18 h.
MS analysis was performed by MS Bioworks (MSB-09). The gel digest was ana-
lyzed by nano LC/MS/MS with a Waters NanoAcquity HPLC system interfaced to
a ThermoFisher Orbitrap Velos Pro. Peptides were loaded on a trapping column
and eluted over a 75-μm analytical column at 350 nL/min; both columns were
packed with Jupiter Proteo resin (Phenomenex). The MS was operated in data-
dependent mode, with MS performed in the Orbitrap at 60,000 full width at
half maximum resolution and MS/MS performed in the Velos. The 15 most
abundant ions were selected for MS/MS.
RT-PCR. Total RNAwas isolated from C2C12 cells using the Quick-RNAMicroPrep
kit (R1050; Zymo Research). Then reverse transcription was performed to gen-
erate cDNA by using the High-Capacity RNA to cDNA kit (4387406; Thermo
Fischer Scientific). Quantitative PCR was performed using gene-specific TaqMan
primers (Invitrogen): 18S (Mm02601777_g1), Hif1α (Mm00468878_m1), Vegfa
(Mm01281449_m1), Pdgfa (Mm01205760_m1), and Pdgfb (Mm00440677_m1),
Fgf2(Mm00433207_m1). Expression levels were analyzed by comparative Ct
(ΔΔCT) with StepOne real-time PCR software (Applied Biosystems).
Western Blots. Cells and tissue were lysed with 25 mmol/L Tris·HCl, 150 mmol/L
NaCl, 10 mmol/L EDTA, 1% Triton, 1× protease, and a phosphatase inhibitor
mixture (PI78441; Thermo Scientific). Samples were incubated with sample
loading buffer (NP0007; Life Technologies) for 5 min at 95 °C. The protein assay
was performed by Bio-Rad DC assay (500-0112; Bio-Rad), and an equal amount
of proteins was separated by SDS/PAGE. For detection of GSH-protein adducts,
proteins were analyzed in the nonreducing condition. After transfer, membranes
were stained with Ponceau S, and images were obtained by scanning and then
destained for the following experiments. After blocking with 5% (wt/vol) skim
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Fig. 3. Lack of Glrx improved ischemic revascularization after hind limb ischemia in mice. (A and B) Blood flow after hind limb ischemia was analyzed by LASER
Doppler. (A) Representative images and (B) quantitative serial assessment (n = 8 each group). (C) Representative H&E staining of nonischemic (Non-Isc) and is-
chemic (Isc) gastrocnemius muscles of WT and Glrx KO mice. Squire area in low-power field images (Left) are shown by high-power images (Right). Black bar is
1 mm for low-power images and 100 μm for high-power field images. (D and E) Capillary density measurement in gastrocnemius muscles of WT and Glrx KO mice
7 d after HLI. Capillaries were stained with fluorescein-conjugated isolectin B4. (D) Representative images. (Scale bar, 50 μm.) (E) Graphical analysis (n = 8 each
group). (F and G) Levels of protein GSH adducts in nonischemic (Non-Isc) and ischemic (Isc) gastrocnemius muscles of WT and Glrx KO mice were detected by anti-
GSH antibody. (F) Representative blot and (G) densitometry analysis. (H–J) Western blot for HIF-1α, VEGF-A, and Glrx expression in muscles. (H) Representative
blot, (I) densitometry analysis of HIF-1α, and (J) densitometry analysis of VEGF-A. Ponceau S staining showed equal loading of proteins and used as loading control
to normalize protein expression (n = 4 each group). †P < 0.05 compared with nonischemic limbs; *P < 0.05.
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milk in PBS with Tween 20 (0.1%) for 1 h, the membranes were incubated with
the specific antibodies overnight at 4 °C, followed by the appropriate HRP-
conjugated second antibody 1 h at room temperature. Images were visualized
by LAS-4000 (GE Healthcare), and densitometry analysis was performed using
ImageJ software (National Institutes of Health).
Histological Assessment. Mouse gastrocnemius muscles were obtained 1 wk
after hind limb ischemia surgery and fixedwith 4%(wt/vol) paraformaldehyde in
PBS for 3 h and transferred to 30% (wt/vol) sucrose overnight. Then the samples
were embedded in OCT compound, frozen, and serially sectioned (6 μm).Muscle
sections were stained with H&E. Capillary density was quantified by staining
with fluorescein-labeled GSL I-isolectin B4 (FL-1201; Vector Laboratory). Capil-
laries in the nonischemic and ischemic muscle were counted using ImageJ
software, averaged from six images (200× magnification).
Biotin Switch Assay. Reversible oxidative cysteine modifications were analyzed
bybiotin switch assay.DifferentiatedC2C12 cellswere treatedwithGSSGester for
10 h. Then, cells were lysed with 25mmol/L Tris·HCl, 150 mmol/L NaCl, 10 mmol/L
EDTA, 1% Triton, and 100 mmol/L maleimide and incubated for 45 min at room
temperature. After desalting with a Zeba column (89889; Thermo Fisher Scien-
tific) to remove free maleimide, samples were reduced with 5 mmol/L DTT for
20 min in a conventional way or 30 mmol/L ascorbate for 1 h for the ascorbate-
dependent biotin switch assay at room temperature. Samples were desalted
again and labeled with 1 mmol/L N-(Biotinoyl)-N′-iodoacetyl ethylenediamine
(BIAM) (90059; Biotium) for 1 h at room temperature. Free BIAM was removed
using the desalting column three times. Then, 200 μg proteins was incubated
with 200 μg streptavidin magnetic beads (S1420S; New England Bio Labs) for 1 h
at 4 °C to pull-down biotin-labeled proteins. After washing three times with lysis
buffer, proteins were eluted with 1× sample loading buffer and analyzed by
Western blot.
Mice. Protocols for all mouse studies were approved by the Institutional Animal
Care and Use Committee at Boston University. Glrx KO mice were originally
generated by Y.-S. Ho (35) (Wayne State University, Detroit, MI) and were
backcrossed to the C57BL/6 background in Yvonne Janssen-Heininger’s
laboratory (University of Vermont, Burlington, VT) and imported to Boston
University. The mice were backcrossed (>10 crosses) onto C57BL/6J. Male Glrx
KO mice and littermate WT controls were used in the present study. Mice are
maintained in the laboratory animal science center at Boston University Medical
Campus, and all procedures were approved by the Institutional Animal Care
and Use Committee at Boston University.
Hind Limb Ischemia Model.Mice were anesthetized with ketamine (100 mg/kg)
and xylazine (10 mg/kg) by i.p. injection. Hind limb ischemia was produced as
described previously (13). Briefly, after ligation of the left femoral artery
proximal to the superficial epigastric artery branch and anterior to the tibial
artery branch, the segment of femoral artery between ligations was excised.
Buprenorphine (0.5 mg/kg) was given before and after surgery for 3 d. Blood
flow recovery was analyzed using LASER Döppler (Moor Instruments). After
mice were anesthetized with ketamine (100mg/kg) and xylazine (10 mg/kg) by
i.p. injection, blood flow recovery was analyzed using LASER Döppler before
and after surgery, as well as on days 3, 7, and 14. Blood flow was expressed as
ratio of ischemic (left) to nonischemic (right).
Statistical Analysis. All group data are expressed as means ± SEM. Statistical
analysis comparing two groups was carried out using the Student unpaired t test.
Analysis of more than two groups was performed either by one-way ANOVA or
two-way ANOVA, followed by the Tukey post hoc comparison test. Sequential
measurements were analyzed by repeated measure one-way ANOVA. P < 0.05
was considered significant. All analysis was carried out using JMP software.
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